Navigation Links
Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
Date:11/20/2012

CRANBURY, N.J., Nov. 20, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 24th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2012 at 3:10 p.m. Eastern Time.  The conference will be held at The New York Plaza, New York.

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs.  A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live audio broadcast will be available through December 3, 2012.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Nanobiotechnology ... offering. An increasing use ... industries is anticipated. Nanotechnology will be applied ... from formulations for optimal delivery to diagnostic ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biochips and Microarrays ... offering. This report is an analysis ... The report starts with a description of technologies ... include array comparative genomic hybridization (CGH), copy number ...
(Date:9/2/2015)... 02, 2015 Research and ... Jain PharmaBiotech,s new report "Gene Therapy - Technologies, ... The markets for gene therapy are difficult to estimate ... and it is marketed in China ... the years 2014-2024. The estimates are based on epidemiology ...
(Date:9/2/2015)... ... 02, 2015 , ... Drug companies increasingly are adopting a ... reveals in its new report that the U.S. will generate the greatest demand ... the most market demand. , BCC Research examines plant-derived drugs in its ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... Development of Farletuzumab for Ovarian CancerAgreement Highlights Lonza,s ... Pa. and BASEL, Switzerland, May 19 Morphotek(R), ... America, and Lonza Group Ltd jointly announced today ... to support the development and manufacturing of a ...
... Therapeutic for IBD with Novel Mode of ActionMOUNTAIN ... Inc., today announced that data from the company,s ... Crohn,s disease Trial) Phase II/III clinical trial of ... will be presented in an oral session at ...
... to present Phase 2 data on perifosine for ... Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ... therapy and oncology, today announced that results supporting ... compound, AEZS-108, in prostate cancer, will be presented ...
Cached Biology Technology:Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 2Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 3Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting 2AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting 3
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... mammals arose in the Triassic period, over 225 million years ... as Morganucodon from England, Megazostrodon from ... differentiated teeth (incisors, canines, molars) and large brains and were ... make them stand apart from their reptile ancestors, and which ...
... 2013) When a woman becomes pregnant, she knows it ... the health of herself and the health of her baby. ... and the Eurpean Federation of Periodontology (EFP) urge pregnant women ... women with periodontal disease may be at risk of adverse ...
... United States there are millions of sports related concussions each ... fear of being benched trumps the fear of permanent brain ... diagnose concussions on the sidelines. , Researchers at San ... , A team led by Daniel Goble, an exercise and ...
Cached Biology News:Not the end of the world: Why Earth's greatest mass extinction was the making of modern mammals 2Expectant mothers' periodontal health vital to health of her baby 2Combating concussions 2Combating concussions 3
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
... The Eclipse C1 Plus is a ... highest-quality digital imaging with an ultra-compact and ... of the C1 Plusboost optical performance to ... acquisition.The system alsoincludes support for X and ...
Biology Products: